Please assess the completion status of the following clinical trial:

Trial Title: Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 12 to 24 months on the day of inclusion~* In good general health, without significant medical history.~* Provision of informed consent form signed by at least one parent or other legally acceptable representative.~* Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures.~Exclusion Criteria:~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.~* Known systemic hypersensitivity to any of IMOJEV™ components or history of a life-threatening reaction to a vaccine containing any of the same substances and vaccination,known systemic hypersensitivity to CD.JEVAX® main components and the other components (including Gelatin, kanamycin, and gentamicin).~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.~* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of the immune response.~* Previous vaccination against flavivirus disease, including Japanese encephalitis (JE).~* Administration of any anti-viral within 2 months preceding Visit 01 and up to the 4 weeks following the trial vaccination.~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for pandemic influenza vaccination, which may be received at least two weeks before the study vaccines.~* Planned receipt of any vaccine from the inclusion up to the 4 weeks following the trial vaccination.~* History of central nervous system disorder or disease, including seizures.~* Planned receipt of any JE vaccine during the course of the study.~* History of flavivirus infection (confirmed either clinically, serologically or virologically).~* Administration of systemic corticosteroids for more than two consecutive weeks within the 4 weeks preceding vaccination.~* Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection 3 days before vaccination as well as the day of vaccination, according to Investigator judgment.~* Thrombocytopenia or bleeding disorder contraindicated for vaccination with same administration route, or receipt of anticoagulants in the 3 weeks preceding inclusion.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- IMOJEV™ Vaccine Group (Type: EXPERIMENTAL): Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.
- CD.JEVAX ™ Vaccine Group (Type: ACTIVE_COMPARATOR): Participants will receive a single dose of the Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine), CD.JEVAX™ on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete